General University Hospital Of Larissa
- Address
- lock Available on a paid plan
General University Hospital Of Larissa - Advanced Clinical Research Center
General University Hospital Of Larissa is a comprehensive medical research institution conducting cutting-edge clinical trials across multiple therapeutic areas. The center demonstrates particular expertise in oncology, immunology, and respiratory medicine, participating in numerous Phase 2 and Phase 3 international studies that advance treatment options for complex diseases.
- Oncology research including breast cancer, lung cancer, bladder cancer, multiple myeloma, and renal cell carcinoma with focus on immunotherapy combinations and targeted therapies
- Neurological and autoimmune conditions including multiple sclerosis, myasthenia gravis, systemic lupus erythematosus, and chronic inflammatory demyelinating polyneuropathy
- Respiratory diseases encompassing COPD, asthma, idiopathic pulmonary fibrosis, and small-cell lung cancer
- Cardiovascular disease prevention, including heart failure prevention and atherosclerotic cardiovascular disease research
The hospital's research portfolio reflects expertise in evaluating novel immunotherapeutic agents, including checkpoint inhibitors, antibody-drug conjugates, and biologic therapies. The center actively participates in studies investigating combination therapies and maintenance treatment strategies, particularly in oncology and autoimmune disorders. Additional areas of investigation include infectious diseases such as candidemia, hematologic malignancies including follicular lymphoma and myelofibrosis, and specialized conditions like pulmonary arterial hypertension, uveitis, and post-acute COVID syndrome, demonstrating the institution's broad clinical research capabilities and commitment to advancing medical science across diverse patient populations.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 3 of 19 therapeutic areas and 15 of 311 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 288 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 52 by active trials.
lock +51 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
lock +33 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 173 other sites in Greece
Therapeutic Area Benchmark — Greece
Select a therapeutic area to compare against other sites in Greece.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Greece
Market Share
Country: Greece
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in General University Hospital Of Larissa
lock Showing 1 of 202 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A 40-Week Randomized Study Evaluating the Efficacy and Safety of Weekly Insulin Icodec/Semaglutide Versus Daily Insulin Glargine in Type 2 Diabetes Patients | Novo Nordisk A/S | Phase III | Not Recruiting | Feb 2024 | Jun 2025 |
IMP list
lock Showing 1 of 311 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Pembrolizumab | 26 | Unknown | 2016-03-15 | 2026-06-01 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.